scholarly journals Practical cardiovascular risk calculator for asymptomatic patients with type 2 diabetes mellitus: PRECISE‐DM risk score

2020 ◽  
Vol 43 (9) ◽  
pp. 1040-1047
Author(s):  
Young Choi ◽  
Yeoree Yang ◽  
Byung‐Hee Hwang ◽  
Eun Young Lee ◽  
Kun Ho Yoon ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Risk Calculator ◽  
Asymptomatic Patients

scholarly journals A Risk Score to Predict Type 2 Diabetes Mellitus in an Elderly Spanish Mediterranean Population at High Cardiovascular Risk

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33437 ◽  
Author(s):  
Marta Guasch-Ferré ◽  
Mònica Bulló ◽  
Bernardo Costa ◽  
Miguel Ángel Martínez-Gonzalez ◽  
Núria Ibarrola-Jurado ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Mediterranean Population ◽  
High Cardiovascular Risk

Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Kazuma Oyama ◽  
Stephen D Wiviott ◽  
Itamar RAZ ◽  
Avivit Cahn ◽  
Erica Goodrich ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Risk Stratification ◽  
Risk Score ◽  
Composite Outcomes ◽  
Risk Categories

Introduction: In DECLARE-TIMI 58, the SGLT-2 inhibitor, dapagliflozin reduced the risk of the composite of cardiovascular death (CVD) or hospitalization for heart failure (HHF), and renal-specific outcomes in a broad range of patients with type 2 diabetes mellitus (T2DM). The TIMI Risk Score for Secondary Prevention (TRS 2°P) is a clinical risk score developed in patients with atherosclerotic cardiovascular disease (ASCVD) that provides risk stratification. Hypothesis: We hypothesized that the TRS 2°P would provide risk stratification in this population and that dapagliflozin would provide cardiovascular protection regardless of risk. Methods: DECLARE-TIMI 58 included patients with T2DM and either multiple risk factors or established ASCVD. Patients were stratified into 3 risk categories based on the 10-point TRS 2°P (see Figure , low: 1 or 2 points, intermediate: 3 points, or high: ≥4 points). Outcomes were major adverse cardiovascular events (MACE) (CVD, myocardial infarction, or ischemic stroke), CVD/HHF, components for MACE, and renal-specific composite outcomes. Results: Low, intermediate, or high risk, comprised respectively 49.8%, 31.2%, and 19.0% of the total of 17159 patients. In the placebo arm, increasing risk category was associated with a higher risk of all the outcomes of interest across risk categories (P-trend<0.001 for each) ( Figure ). The C-statistics were 0.67 for MACE and 0.72 for CVD/HHF in the placebo arm. Relative risk reductions in CVD/HHF and renal-specific composite outcomes with dapagliflozin were consistent for patients across the spectrum of TRS 2°P (P>0.05 for each interaction). Conclusions: Cardiovascular risk stratification using TRS 2°P identifies high-risk patients with T2DM for MACE, CVD/HHF, individual components for MACE, and renal-specific outcomes. Reductions in CVD/HHF and renal-specific outcomes with dapagliflozin versus placebo were consistent across the range of TRS 2°P.

RISK-1: One-year Retrospective Study to Assess Cardiovascular Risk at the Onset of Type 2 Diabetes Mellitus in Slovenia

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154481
Author(s):  
Iris Marolt ◽  
Jana Komel ◽  
Elena Kuzmina ◽  
Anja Babič ◽  
Renata Kopriva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Retrospective Study ◽  
One Year
Sign in / Sign up

Export Citation Format

Share Document